Degradable polymeric implantable medical devices with continuous phase and discrete phase
AssigneeAdvanced Cardiovascular Systems, Inc.
InventorsYunbing Wang, David C. Gale
Life of this patent
Estimating the term…
Abstract
An implantable medical device is disclosed comprising: a structural element, wherein the structural element includes: a continuous phase comprising a first polymer of LPLG; a discrete phase within the continuous phase, wherein the discrete phase comprises a second polymer including rapidly eroding elastic discrete phase segments. The second polymer further includes anchor segments that have the same or substantially the same chemical make up as the first polymer of the continuous phase, and at least some of the anchor segments have partially or completely phase-separated from the discrete phase into the continuous phase.
Claims31
An implantable medical device comprising:
- a structural element, wherein the structural element includes:
- a continuous phase comprising a first polymer of LPLG;
- a discrete phase within the continuous phase, wherein the discrete phase comprises a second polymer including discrete phase segments;
- the second polymer further includes anchor segments that have the same or substantially the same chemical make up as the first polymer of the continuous phase, and at least some of the anchor segments have partially or completely phase-separated from the discrete phase into the continuous phase.
An implantable medical device, comprising:
- a structural element fabricated of a blend that includes about 60 to about 99 wt % of a first polymer of LPLG, wherein the first polymer forms a continuous phase;
- and
- about 1 to about 40 wt % of a second polymer, the second polymer forming a discrete phase within the continuous phase, wherein the second polymer having a Tg below body temperature comprises discrete phase segments that degrade to acidic fragments,
- the second polymer further comprises anchor segments having the same or substantially the same chemical make up as the continuous phase, wherein the anchor segment has phase-separated out from the discrete phase into the continuous phase.
An implantable medical device, comprising:
- a structural element fabricated of a blend that includes:
- about 60 to about 99 wt % of a first polymer of LPLG, wherein the first polymer forms a continuous phase;
- about 1 to about 10 wt % of a second polymer, the second polymer forming a discrete phase within the continuous phase, the second polymer comprising discrete phase segments and anchor segments, wherein anchor segments have the same or substantially the same chemical make up as the first polymer of the continuous phase and have phase-separated out from the discrete phase into the continuous phase;
- and
- about 5 to about 30 wt % of a third polymer having a Tg below body temperature consisting essentially of discrete phase segments, wherein the third polymer degrades into fragments at least some of which are acidic.
A composition comprising:
- a continuous phase comprising a first polymer of LPLG;
- a discrete phase within the continuous phase, wherein the discrete phase comprises a second polymer including discrete phase segments;
- the second polymer further includes anchor segments that have the same or substantially the same chemical make up as the first polymer of the continuous phase, and at least some of the anchor segments have partially or completely phase-separated from the discrete phase into the continuous phase.
A method of forming a copolymer comprising:
- mixing glycolide monomers, caprolactone monomers, a catalyst, and a solvent to form a solution, wherein the glycolide and caprolactone monomers react in the solution to form P(GA-co-CL);
- and adding L-lactide monomers and glycolide monomers and allowing the added monomers to react with P(GA-co-CL) to form P(GA-co-CL)-b-LPLG.
A method of forming a copolymer comprising:
- mixing glycolide monomers, L-lactide monomers, a catalyst, and a solvent to form a solution, wherein the glycolide and L-lactide monomers react in the solution to form LPLG;
- and
- adding caprolactone monomers and glycolide monomers and allowing the added monomers to react with LPLG to form LPLG-b-P(GA-co-CL).
A copolymer comprising P(GA-co-CL)-b-LPLG.
A copolymer comprising LPLG-b-P(GA-co-CL).
Dependencies are inferred from the claim text.